The Pharmaletter

One To Watch

arena_company

Arena Pharmaceuticals

A US company developing a richly diversified portfolio of therapeutic candidates targeting gastroenterology, dermatology and cardiology.

Its pipeline includes four investigational medicines in eight indications and eleven ongoing or planned clinical trials.

Arena’s lead investigational compound in dermatology, etrasimod, is a highly selective, once-daily, oral sphingosine 1-phosphate (S1P) receptor modulator intended to provide systemic and local effects on specific immune cell types with the potential to treat multiple immune-mediated inflammatory diseases, including ulcerative colitis, Crohn's disease, eosinophilic esophagitis, atopic dermatitis, and alopecia areata.

Want to Update your Company's Profile?


More Arena Pharmaceuticals news >